A phase 2a, randomized, crossover trial of gabapentin enacarbil for the treatment of postherpetic neuralgia in gabapentin inadequate responders

Pain Medicine (United States)

Volumn 14, Issue 12, 2013, Pages 1918-1932

  Harden, R Norman ^a   Freeman, Roy ^b   Rainka, Michelle ^c   Zhang, Lixin ^c   Bell, Chris ^d,e   Berges, Alienor ^d,e   Chen, Chao ^d,e   Graff, Ole ^d,e   Harding, Kathleen ^d,e   Hunter, Setrina ^d,e   Kavanagh, Sarah ^d,e   Schwartzbach, Caryl ^d,e   Warren, Samantha ^d,e   Mcclung, Carrie ^d,e  

^a REHABILITATION INSTITUTE OF CHICAGO   (United States)

^b BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

^c DENT NEUROLOGIC INSTITUTE   (United States)

^d GLAXOSMITHKLINE   (United States)

^e GLAXOSMITHKLINE   (United Kingdom)

Author keywords

Gabapentin Enacarbil; Inadequate Responders; PHN; Postherpetic Neuralgia

Indexed keywords

GABAPENTIN; GABAPENTIN ENACARBIL; PARACETAMOL;

ABDOMINAL PAIN; ADULT; AGED; ANALGESIA; ARTICLE; AUDITORY HALLUCINATION; BLOOD PRESSURE; CHEMISTRY; CONSTIPATION; CONTROLLED STUDY; CROSSOVER PROCEDURE; DEPRESSION; DIABETES MELLITUS; DISEASE SEVERITY; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG BLOOD LEVEL; DRUG DOSE COMPARISON; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG ERUPTION; DRUG FATALITY; DRUG INDUCED HEADACHE; DRUG MEGADOSE; DRUG SAFETY; DRUG WITHDRAWAL; DYSPEPSIA; FATIGUE; FEMALE; FOOT EDEMA; GOUT; HEMATOLOGICAL PARAMETERS; HUMAN; HYPERHIDROSIS; IRRITABILITY; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; MEDICAL HISTORY; MULTICENTER STUDY; MYALGIA; NAUSEA; NEPHROLITHIASIS; OPEN STUDY; OUTCOME ASSESSMENT; PAIN ASSESSMENT; PERIPHERAL EDEMA; PHASE 2 CLINICAL TRIAL; POSTHERPETIC NEURALGIA; RANDOMIZED CONTROLLED TRIAL; RHINOPHARYNGITIS; SCORING SYSTEM; SIDE EFFECT; SINUSITIS; SOMNOLENCE; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT RESPONSE; URINALYSIS; VITAL SIGN;

GABAPENTIN ENACARBIL; INADEQUATE RESPONDERS; PHN; POSTHERPETIC NEURALGIA;

ADULT; AGED; AGED, 80 AND OVER; ANALGESICS; CARBAMATES; CROSS-OVER STUDIES; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; FEMALE; GAMMA-AMINOBUTYRIC ACID; HUMANS; MALE; MIDDLE AGED; NEURALGIA, POSTHERPETIC; PAIN MEASUREMENT; PRODRUGS; TREATMENT OUTCOME;

EID: 84890233568     PISSN: 15262375     EISSN: 15264637     Source Type: Journal    
DOI: 10.1111/pme.12227     Document Type: Article

References (43)

1. Cluff RS, Rowbotham MC. Pain caused by herpes zoster infection. Neurol Clin 1998;16:813-832.
2. Dworkin RH, Boon RJ, Griffin DR, Phung D. Postherpetic neuralgia: Impact of famciclovir, age, rash severity, and acute pain in herpes zoster patients. J Infect Dis 1998;178(suppl 1):S76-80.
3. Bowsher D. The lifetime occurrence of herpes zoster and prevalence of post-herpetic neuralgia: A retrospective survey in an elderly population. Eur J Pain 1999;3:335-342.
4. Desmond RA, Weiss HL, Arani RB, etal. Clinical applications for change-point analysis of herpes zoster pain. J Pain Symptom Manage 2002;23:510-516.
5. Dworkin RH, Portenoy RK. Pain and its persistence in herpes zoster. Pain 1996;67:241-251.
6. Gershon AA. Epidemiology and management of postherpetic neuralgia. Semin Dermatol 1996;15(2 suppl 1):8-13.
7. Harpaz R, Ortega-Sanchez IR, Seward JF. Advisory Committee on Immunization Practices (ACIP) Centers for Disease Control and Prevention (CDC). Prevention of herpes zoster: Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 1997;57:1-30.
8. Goh CL, Khoo L. A retrospective study of the clinical presentation and outcome of herpes zoster in a tertiary dermatology outpatient referral clinic. Int J Dermatol 1997;36:667-672.
9. Kost RG, Straus SE. Postherpetic neuralgia-pathogenesis, treatment and prevention. N Engl J Med 1996;335:32-42.
10. Lee JJ, Gauci CA. Postherpetic neuralgia: Current concepts and management. Br J Hosp Med 1994;52:565-567, 570.
11. Schamder K. Postherpetic neuralgia in immunocompetent elderly people. Vaccine 1998;16:1768-1770.
12. Choo PW, Galil K, Donahue JG, etal. Risk factors for postherpetic neuralgia. Arch Intern Med 1997;157:1217-1224.
13. Stankus SJ, Dlugopolski M, Packer D. Management of herpes zoster (shingles) and postherpetic neuralgia. Am Fam Physician 2000;61:2437-2444, 2447-8.
14. Dworkin RH, Malone DC, Panarites CJ, Armstrong EP, Pham SV. Impact of postherpetic neuralgia and painful diabetic peripheral neuropathy on health care costs. J Pain 2010;11:360-368.
15. White RR, Lenhart G, Singhal PK, etal. Incremental 1-year medical resource utilization and costs for patients with herpes zoster from a set of US health plans. Pharmacoeconomics 2009;27:781-792.
16. Doth AH, Hansson PT, Jensen MP, Taylor RS. The burden of neuropathic pain: A systematic review and meta-analysis of health utilities. Pain 2010;149:338-344.
17. Johnson RW, Bouhassira D, Kassianos G, etal. The impact of herpes zoster and post-herpetic neuralgia on quality of life. BMC Med 2010;21:37.
18. Gnann JW, Whitley RJ. Clinical practice. Herpes zoster. N Engl J Med 2002;347:340-346.
19. Johnson RW. Consequences and management of pain in herpes zoster. J Infect Dis 2002;186(suppl 1):S83-90.
20. Irving G, Backonja M, Rauck R, etal. NGX-4010, a capsaicin 8% dermal patch, administered alone or in combination with systemic neuropathic pain medications, reduces pain in patients with postherpetic neuralgia. Clin J Pain 2012;28:101-107.
21. Dworkin RH, Turk DC, Peirce-Sandner S, etal. Placebo and treatment group responses in postherpetic neuralgia vs. painful diabetic peripheral neuropathy clinical trials in the REPORT database. Pain 2010;150:12-16.
22. Backonja M, Wallace MS, Blonsky ER, etal. NGX-4010 C116 Study Group. NGX-4010, a high-concentration capsaicin patch, for the treatment of postherpetic neuralgia: A randomised, double-blind study. Lancet Neurol 2008;7(12):1106-1112.
23. Backonja MM, Canafax DM, Cundy KC. Efficacy of gabapentin enacarbil vs placebo in patient with postherpetic neuralgia and a pharmacokinetic comparison with oral gabapentin. Pain Med 2011;12:1090-1108.
24. Neurontin® (gabapentin) Prescribing Information. New York (NY): Pfizer, Inc.; 2012. Available at: http://labeling.pfizer.com/ShowLabeling.aspx?id=630 (accessed March 2012).
25. Rice ASC, Maton S. Gabapentin in postherpetic neuralgia: A randomized, double-blind, placebo controlled trial. Pain 2001;94:215-224.
26. Rowbotham M, Harden N, Stacey B, Bernstein P, Magnus-Miller L. Gabapentin for the treatment of postherpetic neuralgia. A randomized controlled trial. JAMA 1998;280:1837-1842.
27. Stewart BH, Kugler AR, Thompson PR, Bockbrader HN. A saturable transport mechanism in the intestinal absorption of gabapentin is the underlying cause of the lack of proportionality between increasing dose and drug levels in plasma. Pharm Res 1993;10:276-281.
28. Cundy KC, Annamaliai T, Bu L, etal. XP13512 [((±)-1-([(α-Isobutanyuloxyethoxy)carbonyl]aminomethyl)-1-cyclohexane acetic acid], a novel gabapentin prodrug: II. Improved oral bioavailability, dose proportionality, and colonic absorption compared with gabapentin in rats and monkeys. J Pharmacol Exp Ther 2004;311:324-333.
29. Dworkin RH, Turk DC, Farrar JT, etal. Core outcome measures for chronic pain clinical trials: IMMPACT recommendations. Pain 2005;113:9-19.
30. Farrar JT, Young JP, Lamoreaux L, Weth J, Poole RM. Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale. Pain 2001;94:149-158.
31. Guy W. ECDEU Assessment Manual for Psychopharmacology (DHEW Publication No ADM 76-338). Washington, DC: US Government Printing Office; 1976.
32. Cleeland CS, Ryan KM. Pain assessment: Global use of the brief pain inventory. Ann Acad Med Singapore 1994;23:129-138.
33. Beal S, Sheiner LB, Boeckmann A, Bauer RJ. NONMEM User's Guide (1989-2009). Ellicott City, MD: Icon Development Solutions; 2009.
34. Carlsson KC, van de Schootbrugge M, Eriksen HO, etal. A population pharmacokinetic model of gabapentin developed in nonparametric adaptive grid and nonlinear mixed effects modeling. Ther Drug Monit 2009;31:86-94.
35. Lal R, Sukbuntherng J, Luo W, etal. Population pharmacokinetics and pharmacodynamics of gabapentin after administration of gabapentin enacarbil. J Clin Pharmacol 2013;53:29-40.
36. Ouellet D, Bockbrader HN, Wesche DL, Shapiro DY, Garofalo E. Population pharmacokinetics of gabapentin in infants and children. Epilepsy Res 2001;47:229-241.
37. Freynhagen R, Strojek K, Griesing T, Whalen E, Balkenohl M. Efficacy of pregabalin in neuropathic pain evaluated in a 12-week, randomised, double-blind, multicentre, placebo-controlled trial of flexible- and fixed-dose regimens. Pain 2005;115:254-263.
38. Max M. Is mechanism-based pain treatment attainable? Clinical trial issues. J Pain 2000;1(suppl 1):2-9.
39. Swartzman L, Burkell J. Expectations and the placebo effect in clinical drug trials: Why we should not turn a blind eye to unblinding, and other cautionary notes. Clin Pharmacol Ther 1998;64:1-7.
40. Hróbjartsson A, Gøtzsche PC. Is the placebo powerless? An analysis of clinical trials comparing placebo with no treatment. N Engl J Med 2001;344:1594-1602.
41. Clayden JR, Bell JW, Pollard P. Menopausal flushing: Double-blind trial of a non-hormonal medication. BMJ 1974;1:409-412.
42. Colagiuri B. Participant expectancies in double-blind randomized placebo-controlled trials: Potential limitations to trial validity. Clin Trials 2010;7:246-255.
43. Rutherford BR, Rose SA, Sneed JR, Roose SP. Study design affects participant expectations a survey. J Clin Psychopharmacol 2009;29:179-181.